Prevention and Management of Tuberculosis in Solid Organ Transplant Recipients

• Autores: David J. Epstein, Aruna K. Subramanian
• Localización: Infectious disease clinics of North America, ISSN 0891-5520, Vol. 32, Nº. 3, 2018 (Ejemplar dedicado a: Management of Infections in Solid Organ Transplant Recipients), págs. 703-718
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Solid organ transplant recipients are at an increased risk of tuberculosis and transplant candidates should be screened early in their evaluation with a detailed history, tuberculin skin test or tuberculosis interferon-gamma release assay, and chest radiograph. For latent tuberculosis treatment, isoniazid and rifamycin-based regimens have advantages and disadvantages; treatment decisions should be customized. Tuberculosis after solid organ transplantation generally occurs after months or years; early infections should raise the possibility of donor-derived infections. Tuberculosis diagnosis and treatment in solid organ transplant recipients may be complicated by protean manifestations, drug interactions, and adverse drug reactions.